Skip to content
OpenCapital
Get started
Kymera Therapeutics logo

Kymera Therapeutics (KYMR) Q1 2026 Earnings

KYMR·Reported April 30, 2026·Before market open

Kymera Therapeutics reported Q1 2026 revenue of $34.4M (+55.5% YoY), beat analyst consensus of $8.3M by $26.1M. Diluted EPS came in at $-0.71 (+13.4% YoY), beat the $-0.89 consensus by $0.18.

Revenue
$34.4Mbeat by $26.1M
Consensus: $8.3M
Diluted EPS
$-0.71beat by $0.18
Consensus: $-0.89
SEC

SEC Filings

Earnings release8-K · 0001193125-26-193957
Quarterly report10-Q · 0001193125-26-193967

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Kymera Therapeutics's Q1 2026 earnings report.

Kymera Therapeutics (KYMR) reported Q1 2026 earnings on April 30, 2026 before market open.

Kymera Therapeutics reported revenue of $34.4M and diluted EPS of $-0.71 for Q1 2026.

Revenue beat the consensus estimate of $8.3M by $26.1M. EPS beat the consensus estimate of $-0.89 by $0.18.

Compared to the same quarter a year prior, revenue grew 55.5% from $22.1M a year earlier and diluted EPS grew 13.4% from $-0.82.

You can read the 8-K earnings release (0001193125-26-193957) and the 10-Q periodic report (0001193125-26-193967) directly on SEC EDGAR. The filing index links above go to sec.gov.